NASDAQ:EVLO - Evelo Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.71 +0.52 (+5.66 %) (As of 02/19/2019 04:00 PM ET)Previous Close$9.19Today's Range$9.28 - $9.9052-Week Range$6.51 - $16.75Volume32,500 shsAverage Volume66,215 shsMarket Capitalization$308.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Receive EVLO News and Ratings via Email Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVLO Previous Symbol CUSIPN/A Webwww.evelobio.com Phone617-577-0300Debt Debt-to-Equity Ratio0.09 Current Ratio17.86 Quick Ratio17.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-28,040,000.00 Net MarginsN/A Return on Equity-101.03% Return on Assets-37.47%Miscellaneous Employees59 Outstanding Shares31,769,000Market Cap$308.48 million OptionableNot Optionable Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions What is Evelo Biosciences' stock symbol? Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO." How were Evelo Biosciences' earnings last quarter? Evelo Biosciences Inc (NASDAQ:EVLO) posted its quarterly earnings results on Thursday, February, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.09. View Evelo Biosciences' Earnings History. When is Evelo Biosciences' next earnings date? Evelo Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, May 30th 2019. View Earnings Estimates for Evelo Biosciences. What price target have analysts set for EVLO? 5 analysts have issued twelve-month target prices for Evelo Biosciences' shares. Their predictions range from $10.00 to $30.00. On average, they expect Evelo Biosciences' stock price to reach $22.75 in the next twelve months. This suggests a possible upside of 134.3% from the stock's current price. View Analyst Price Targets for Evelo Biosciences. What is the consensus analysts' recommendation for Evelo Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evelo Biosciences. Has Evelo Biosciences been receiving favorable news coverage? Press coverage about EVLO stock has trended somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evelo Biosciences earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are some of Evelo Biosciences' key competitors? Some companies that are related to Evelo Biosciences include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Homology Medicines (FIXX), CannTrust (CNTTF), Advanz Pharma (CXRXF) and Retrophin (RTRX). Who are Evelo Biosciences' key executives? Evelo Biosciences' management team includes the folowing people: Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)Mr. Jonathan Poole, Chief Financial Officer (Age 44) When did Evelo Biosciences IPO? (EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. Who are Evelo Biosciences' major shareholders? Evelo Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.11%), Northern Trust Corp (0.40%), Geode Capital Management LLC (0.28%), Victory Capital Management Inc. (0.28%), Bank of New York Mellon Corp (0.12%) and Jane Street Group LLC (0.06%). View Institutional Ownership Trends for Evelo Biosciences. Which major investors are selling Evelo Biosciences stock? EVLO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Evelo Biosciences. Which major investors are buying Evelo Biosciences stock? EVLO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Essex Investment Management Co. LLC, Essex Investment Management Co. LLC, Larson Financial Group LLC and American International Group Inc.. View Insider Buying and Selling for Evelo Biosciences. How do I buy shares of Evelo Biosciences? Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Evelo Biosciences' stock price today? One share of EVLO stock can currently be purchased for approximately $9.71. How big of a company is Evelo Biosciences? Evelo Biosciences has a market capitalization of $308.48 million. Evelo Biosciences employs 59 workers across the globe. What is Evelo Biosciences' official website? The official website for Evelo Biosciences is http://www.evelobio.com. How can I contact Evelo Biosciences? Evelo Biosciences' mailing address is 620 Memorial Drive Suite 200 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected] MarketBeat Community Rating for Evelo Biosciences (NASDAQ EVLO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 62 (Vote Outperform)Underperform Votes: 85 (Vote Underperform)Total Votes: 147MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote "Outperform" if you believe EVLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is insider trading?